Exploring the phenotype of Italian patients with ALS with intermediateATXN2polyQ repeats
| العنوان: | Exploring the phenotype of Italian patients with ALS with intermediateATXN2polyQ repeats |
|---|---|
| المؤلفون: | Adriano Chio, Cristina Moglia, Antonio Canosa, Umberto Manera, Maurizio Grassano, Rosario Vasta, Francesca Palumbo, Salvatore Gallone, Maura Brunetti, Marco Barberis, Fabiola De Marchi, Clifton Dalgard, Ruth Chia, Gabriele Mora, Barbara Iazzolino, Laura Peotta, Bryan Traynor, Lucia Corrado, Sandra D'Alfonso, Letizia Mazzini, Andrea Calvo |
| المصدر: | Journal of Neurology, Neurosurgery & Psychiatry. 93:1216-1220 |
| بيانات النشر: | BMJ, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Psychiatry and Mental health, GENETICS, Surgery, Neurology (clinical), ALS |
| الوصف: | ObjectiveTo detect the clinical characteristics of patients with amyotrophic lateral sclerosis (ALS) carrying an intermediateATXN2polyQ number of repeats in a large population-based series of Italian patients with ALS.MethodsThe study population includes 1330 patients with ALS identified through the Piemonte and Valle d’Aosta Register for ALS, diagnosed between 2007 and 2019 and not carryingC9orf72, SOD1, TARDBPandFUSmutations. Controls were 1274 age, sex and geographically matched Italian subjects, identified through patients’ general practitioners.ResultsWe found 42 cases and 4 controls with≥31 polyQ repeats, corresponding to an estimated OR of 10.4 (95% CI 3.3 to 29.0). Patients with≥31 polyQ repeats (ATXN2+) compared with those without repeat expansion (ATXN2−) had more frequently a spinal onset (p=0.05), a shorter diagnostic delay (p=0.004), a faster rate of ALSFRS-R progression (p=0.004) and King’s progression (p=0.004), and comorbid frontotemporal dementia (7 (28.0%) vs 121 (13.4%), p=0.037). ATXN2+ patients had a 1-year shorter survival (ATXN2+ patients 1.82 years, 95% CI 1.08 to 2.51; ATXN2− 2.84 years, 95% CI 1.67 to 5.58, p=0.0001).ATXN2polyQ intermediate repeats was independently related to a worse outcome in Cox multivariable analysis (p=0.006).ConclusionsIn our population-based cohort, ATXN2+ patients with ALS have a distinctive phenotype, characterised by a more rapid disease course and a shorter survival. In addition, ATXN2+ patients have a more severe impairment of cognitive functions. These findings have relevant implications on clinical practice, including the possibility of refining the individual prognostic prediction and improving the design of ALS clinical trials, in particular as regards as those targeted explicitly toATXN2. |
| تدمد: | 1468-330X 0022-3050 |
| DOI: | 10.1136/jnnp-2022-329376 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a02c47edc0650533d3d552b1d6f946 https://doi.org/10.1136/jnnp-2022-329376 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a8a02c47edc0650533d3d552b1d6f946 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1468330X 00223050 |
|---|---|
| DOI: | 10.1136/jnnp-2022-329376 |